Office in Russia. Received revenues in Russia in 2022-2024. Dr Reddy’s Laboratories Ltd has infused ₹565.4 crore into its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19% equity stake in the step-down wholly-owned subsidiary. The investment, made on July 25, 2025, follows board approval granted on November 5, 2024, to inject up to ₹600 crore into the Russian entity. The capital was infused via cash and will be used to support DRL Russia’s working capital requirements. DRL Russia, which operates as a pharmaceutical distribution company in the Russian Federation, reported a turnover of ₹2,347 crore in FY25.